Survivors of infant atypical teratoid/rhabdoid tumors present with severely impaired cognitive functions especially for fluid intelligence and visual processing: data from the German brain tumor studies
Thomas Traunwieser(University Hospital Augsburg), Michael C. Frühwald(University Hospital Augsburg), Stefan Rutkowski(Universität Hamburg), Elena Loos(University Hospital Augsburg), Brigitte Bison(University of Augsburg), Daniela Kandels(University of Augsburg), Anne Neumann‐Holbeck(Universität Hamburg), Matthias Eyrich(University of Würzburg), Petra Neumayer(University Hospital Augsburg), Andrea Kreisch(University Hospital Carl Gustav Carus), Astrid Gnekow(University Hospital Augsburg), Walther Stamm(University Children's Hospital Tübingen), Jenny Prüfe(Heidelberg University), Beate Timmermann(Essen University Hospital), Kristin Faulstich‐Ritter(Universität Ulm), Eva Manteufel(Justus-Liebig-Universität Gießen), Katja Baust(University Hospital Bonn), Karolina Nemes, Alexandra Nest(University Children's Hospital Tübingen), Holger Ottensmeier(Universitätsklinikum Würzburg), Peggy Lüttich(German Cancer Research Center), Martin Mynarek(Universität Hamburg), Lisa Schubert(Universitätsklinikum Würzburg), Katharina Gastberger(University Hospital Augsburg), Paul‐Gerhardt Schlegel, Joachim Gerß, Judyta Landmann(Medizinische Hochschule Hannover), Rainer John(Humboldt-Universität zu Berlin)
Cited by 8
Related Papers
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488